These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 21966329)

  • 1. Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
    Lotfy M; Singh J; Kalász H; Tekes K; Adeghate E
    Open Med Chem J; 2011; 5(Suppl 2):82-92. PubMed ID: 21966329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based therapies in type 2 diabetes mellitus.
    Chia CW; Egan JM
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
    Havale SH; Pal M
    Bioorg Med Chem; 2009 Mar; 17(5):1783-802. PubMed ID: 19217790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Deacon CF
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.
    Pratley RE; Gilbert M
    Rev Diabet Stud; 2008; 5(2):73-94. PubMed ID: 18795210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incretin hormones: from scientific discovery to practical therapeutics.
    Mudaliar S; Henry RR
    Diabetologia; 2012 Jul; 55(7):1865-8. PubMed ID: 22555471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase IV inhibitors and diabetes therapy.
    McIntosh CH
    Front Biosci; 2008 Jan; 13():1753-73. PubMed ID: 17981665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
    Matuszek B; Lenart-Lipińska M; Nowakowski A
    Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.